ANAVEX ADDS DR. PAUL AISEN TO SCIENTIFIC ADVISORY BOARD
(AVXL.OB) today announced the appointment of Dr.
Scientific Advisory Board (SAB) as a clinical expert. The SAB works
closely with the company to support development of the Anavex product
pipeline, including its lead compound ANAVEX 2-73, which is being
studied for Alzheimer’s disease and is scheduled to enter Phase I
clinical trials shortly.
Dr. Aisen is a leading clinician and researcher in Alzheimer’s disease
clinical trials and is on the faculty of the
San Diego
primary research interests focus on the development of new strategies
for the treatment of Alzheimer’s disease. Since 2007, Dr. Aisen has
been Director of the Alzheimer’s Disease Cooperative Study, a
consortium funded by the National Institute on Aging (NIA) to develop
assessment instruments and conduct clinical trials. Dr. Aisen is
Associate Editor of Alzheimer’s Research and Therapy, a major
international peer-reviewed journal, and sits on the editorial board of
BMC Medicine. He has published more than 180 peer-reviewed papers.
“We are delighted that Dr. Aisen has agreed to join the Anavex
Scientific Advisory Board. Dr. Aisen is one of the world’s leading
clinical trials research scientists in the field of Alzheimer’s
disease. His contributions in the development of ANAVEX 2-73 will be
of great importance as we enter clinical trials,” said Dr.
Durrant
“I am excited to be assisting Anavex in their endeavors, since my career
efforts have been directed towards the development of better therapies
for Alzheimer’s disease. We all know that the first drug to treat
Alzheimer’s disease came out in 1993 but we are in need of better
therapies. I sincerely hope that ANAVEX 2-73, with its unique sigma-1
receptor agonism as well as muscarinic and cholinergic effects, as we
have seen in pre-clinical data, will have an impact on the disease
process and treatment in patients,” said Dr. Aisen.
About Alzheimer’s
While Alzheimer’s is most common in people over the age of 65, it can
strike adults of any age irrespective of their gender, background or
socioeconomic status. According to the Alzheimer’s Association an
estimated 5.3 million Americans are currently living with Alzheimer’s
disease. The number of Americans aged 65 and over with Alzheimer’s is
estimated to reach 7.7 million in 2030. By 2050, between 11 million
and 16 million Americans over 65 are expected to have Alzheimer’s
disease.
About ANAVEX 2-73
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs
being studied to potentially treat Alzheimer’s disease itself, versus
treating its symptoms.Â
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the discovery and
development of novel drug candidates for the treatment of neurological
diseases and cancer. The Anavex proprietary SIGMACEPTOR(TM) Discovery
Platform involves the rational design of drug compounds targeted to
specific receptors involved in the modulation of multiple cellular
biochemical signaling pathways.
The SIGMACEPTOR(TM)-N program involves the development of novel drug
candidates that target neurological and neurodegenerative diseases
(Alzheimer’s disease, epilepsy, depression, pain). The company’s lead
drug candidates exhibit high affinity for sigma receptors, which have
been extensively documented as potentially valuable drug targets and
have demonstrated anti-amnesic and neuroprotective properties.
Anavex is a publicly traded company under the symbol “AVXL”.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that ANAVEX 2-73 is scheduled to enter Phase I
clinical trials shortly; that Dr. Aisens’ contributions in the
development of ANAVEX 2-73 will be of great importance; that ANAVEX
2-73 will have an impact on the disease process and treatment in
patients and that ANAVEX 2-73 is the first of a new class of oral,
disease-modifying drugs being studied to potentially treat Alzheimer’s
disease itself, versus treating its symptoms. Actual events or results
may differ materially from those projected in any of such statements
due to various factors, including the risks and uncertainties inherent
in drug discovery and development, which include, without limitation,
the potential failure of development candidates to advance through
preclinical studies or demonstrate safety and efficacy in clinical
testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to retain key employees and our ability to
finance development or satisfy the rigorous regulatory requirements for
new drugs. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.Â
All forward-looking statements are qualified in their entirety by this
cautionary statement and Anavex Life Sciences Corp. undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development
Email: info@anavex.com
Shareholder & Media Relations
Toll-free: 1-866-505-2895
Outside
Email: ir@anavex.com
www.anavex.com
SOURCE Anavex Life Sciences Corp.